Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
7
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
1 terminated/withdrawn out of 7 trials
80.0%
-6.5% vs industry average
71%
5 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Comparative Study of Bupivacaine and Ropivacaine in Lumber Epidural Lower Limb Bypass Surgery
Role: collaborator
Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh
Role: collaborator
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Role: lead
Prevalence and Management Practice of Diabetic Kidney Disease at BADAS Affiliated Healthcare Centres in Bangladesh
Role: lead
Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
Role: lead
Reference Interval of Vitamin D of Coastal Fishermen in Cox's Bazar District of Bangladesh
Role: lead
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
Role: collaborator
All 7 trials loaded